Total Payments
$125,024
2024 Payments
$17,524
Companies
20
Transactions
145
Medicare Patients
633
Medicare Billing
$118,389
Payment Breakdown by Category
Consulting$72,736 (58.2%)
Other$26,586 (21.3%)
Research$11,599 (9.3%)
Travel$9,957 (8.0%)
Food & Beverage$4,132 (3.3%)
Education$15.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $72,736 | 35 | 58.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,926 | 28 | 20.7% |
| Unspecified | $11,599 | 5 | 9.3% |
| Travel and Lodging | $9,957 | 25 | 8.0% |
| Food and Beverage | $4,132 | 50 | 3.3% |
| Honoraria | $660.00 | 1 | 0.5% |
| Education | $15.00 | 1 | 0.0% |
Payments by Type
General
$113,426
140 transactions
Research
$11,599
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $26,190 | 29 | $0 (2021) |
| Merck Sharp & Dohme LLC | $15,237 | 15 | $0 (2024) |
| Genentech, Inc. | $11,989 | 17 | $0 (2024) |
| Exelixis Inc. | $11,239 | 12 | $0 (2024) |
| AbbVie Inc. | $11,037 | 9 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $9,705 | 13 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,124 | 4 | $0 (2024) |
| Eisai Inc. | $6,753 | 10 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $4,496 | 2 | $0 (2022) |
| AstraZeneca UK Limited | $4,453 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,524 | 13 | Regeneron Pharmaceuticals, Inc. ($7,124) |
| 2023 | $18,064 | 19 | AbbVie Inc. ($11,037) |
| 2022 | $16,270 | 12 | Ipsen Biopharmaceuticals, Inc ($4,496) |
| 2021 | $12,066 | 9 | Merck Sharp & Dohme Corporation ($3,330) |
| 2020 | $10,778 | 5 | F. Hoffmann-La Roche AG ($6,193) |
| 2019 | $19,734 | 31 | Genentech, Inc. ($6,351) |
| 2018 | $28,744 | 42 | F. Hoffmann-La Roche AG ($12,288) |
| 2017 | $1,844 | 14 | Halozyme Inc ($1,246) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,640.00 | General |
| 11/07/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,450.00 | General |
| 08/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $476.29 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,155.00 | General |
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,662.00 | General |
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $831.00 | General |
| 06/26/2024 | JAZZ PHARMACEUTICALS INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $780.00 | General |
| 06/20/2024 | JAZZ PHARMACEUTICALS INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| 05/30/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $660.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| 01/19/2024 | Genentech, Inc. | Avastin (Biological), Tecentriq | Food and Beverage | In-kind items and services | $39.68 | General |
| Category: BioOncology | ||||||
| 10/26/2023 | Genentech, Inc. | Avastin (Biological), Tecentriq | — | Cash or cash equivalent | $1,406.25 | Research |
| Study: ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS • Category: BioOncology | ||||||
| 09/20/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $7,425.00 | General |
| 09/20/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $87.00 | General |
| 09/20/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $54.78 | General |
| 06/05/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 05/10/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,745.00 | General |
| 04/04/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $424.70 | General |
| Category: Oncology | ||||||
| 03/26/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $2,933.48 | General |
| 03/25/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $236.04 | General |
| 03/25/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $43.11 | General |
| 03/25/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $10.77 | General |
| 03/25/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $10.77 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTICENTER PHASE Ib STUDY OF THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH BEVACIZUMAB ANDOR OTHER TREATMENTS IN PATIENTS WITH SOLID TUMORS | F. Hoffmann-La Roche AG | $6,193 | 1 |
| A PHASE 1B 2, OPEN LABEL, DOSE ESCALATION STUDY OF MGD007, A HUMANIZED GPA33 CD3 DART PROTEIN IN COMBINATION WITH MGA012, AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY METASTATIC COLORECTAL CARCINOMA | MacroGenics, Inc. | $2,044 | 1 |
| AN OPEN-LABEL, MULTICENTER PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED IN COMBINATION WITH BEVACIZUMAB ANDOR OTHER TREATMENTS IN PATIENTS WITH SOLID TUMORS | F. Hoffmann-La Roche AG | $1,956 | 2 |
| ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | Genentech, Inc. | $1,406 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 106 | 272 | $103,980 | $22,468 |
| 2022 | 5 | 118 | 291 | $108,425 | $23,584 |
| 2021 | 6 | 167 | 469 | $181,640 | $40,625 |
| 2020 | 7 | 242 | 465 | $160,585 | $31,712 |
Total Patients
633
Total Services
1,497
Medicare Billing
$118,389
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 225 | $84,375 | $17,835 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 21 | $10,395 | $2,542 | 24.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $5,640 | $1,321 | 23.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 13 | 14 | $3,570 | $770.48 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 225 | $84,375 | $18,150 | 21.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 28 | $7,000 | $1,686 | 24.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $8,050 | $1,614 | 20.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 12 | $5,940 | $1,484 | 25.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 11 | 12 | $3,060 | $649.98 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 374 | $140,250 | $31,348 | 22.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 28 | $13,860 | $3,526 | 25.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $9,775 | $1,986 | 20.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $7,810 | $1,746 | 22.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 18 | 25 | $6,375 | $1,375 | 21.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 14 | $3,570 | $643.83 | 18.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 222 | $83,250 | $15,194 | 18.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 44 | 74 | $27,750 | $4,918 | 17.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 36 | 64 | $17,630 | $4,485 | 25.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 21 | $10,395 | $2,050 | 19.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 24 | 26 | $6,500 | $1,617 | 24.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 12 | 12 | $5,640 | $1,434 | 25.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 23 | 27 | $6,885 | $1,145 | 16.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 16 | 19 | $2,535 | $869.82 | 34.3% |
About Dr. Stacey Stein, MD
Dr. Stacey Stein, MD is a Hematology & Oncology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285824706.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stacey Stein, MD has received a total of $125,024 in payments from pharmaceutical and medical device companies, with $17,524 received in 2024. These payments were reported across 145 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($72,736).
As a Medicare-enrolled provider, Stein has provided services to 633 Medicare beneficiaries, totaling 1,497 services with total Medicare billing of $118,389. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location New Haven, CT
- Active Since 07/31/2007
- Last Updated 12/03/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285824706
Products in Payments
- TECENTRIQ (Biological) $16,905
- Avastin (Biological) $16,551
- IMFINZI (Biological) $9,518
- Cabometyx (Drug) $8,929
- Lenvima (Drug) $6,753
- Tecentriq (Biological) $6,193
- ONIVYDE (Drug) $4,496
- OPDIVO (Biological) $3,515
- Nexavar (Drug) $2,509
- CABOMETYX (Drug) $2,310
- KEYTRUDA (Biological) $1,683
- QINLOCK (Drug) $525.00
- LIBTAYO (Biological) $476.29
- IMJUDO (Biological) $424.70
- TRUSELTIQ (Drug) $129.14
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $15.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New Haven
Amer Zeidan
Hematology & Oncology — Payments: $934,438
Hematology & Oncology $934,438
Dr. Daniel Petrylak, M.d, M.D
Hematology & Oncology — Payments: $642,957
Hematology & Oncology $642,957
Cheryl Mensah, M.d, M.D
Hematology & Oncology — Payments: $236,631
Hematology & Oncology $236,631
Walid Shaib, M.d, M.D
Hematology & Oncology — Payments: $89,344
Hematology & Oncology $89,344
Dr. Iris Isufi, M.d, M.D
Hematology & Oncology — Payments: $88,237
Hematology & Oncology $88,237
Dr. Shalin Kothari, Md, MD
Hematology & Oncology — Payments: $22,139
Hematology & Oncology $22,139